Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

7.530 -0.090 (-1.18%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
How Is The Market Feeling About Organon? ↗
Organon's (NYSE:OGN) short percent of float has risen 11.91% since its last report. The company recently reported that it has 5.94 million shares sold short, which is 2.63% of all regular shares that... 
Via Benzinga
News headline image
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings ↗
 
Via Benzinga
News headline image
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 297 companies achieved new lows for the year. 
Via Benzinga
News headline image
This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73% ↗
Raymond James cut the price target for PolyPid Ltd. (NASDAQ: PYPD) from $15 to $4. PolyPid shares fell 7.7% to $1.32 in pre-market trading. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 238 companies achieved new lows for the year. 
Via Benzinga
News headline image
This Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring' ↗
 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
From Organon & Co.
Via Business Wire
News headline image
A Look Into Healthcare Sector Value Stocks ↗
  Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Organon: Q2 Earnings Insights ↗
  Organon (NYSE:OGN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Organon reported in-line EPS of $1.25... 
Via Benzinga
News headline image
Organon Reports Results for the Second Quarter Ended June 30, 2022
From Organon & Co.
Via Business Wire
News headline image
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
From Organon & Co.
Via Business Wire
News headline image
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
From Organon & Co.
Via Business Wire
News headline image
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange ↗
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global... 
Via Talk Markets
News headline image
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
From Organon & Co.
Via Business Wire
News headline image
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
From Organon & Co.
Via Business Wire
News headline image
Market Selloff ↗
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
News headline image
Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up ↗
The firm's biggest product sustained a hit due to exchange rates and buying patterns. 
Via Investor's Business Daily
News headline image
Organon Reports Results for the First Quarter Ended March 31, 2022
From Organon & Co.
Via Business Wire
News headline image
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
From Organon & Co.
Via Business Wire
News headline image
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment ↗
Organon & Co (NYSE: OGN)  
Via Benzinga
News headline image
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
From Organon & Co.
Via Business Wire
News headline image
Healthy Pharma Favorites ↗
Here's a look at two drug makers that we recommend in our Growth & Income Portfolio. The stocks in this portfolio are generally higher-quality, larger-cap companies that have fallen out of favor. 
Via Talk Markets
News headline image
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar ↗
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
Via Benzinga
News headline image
Overview Of Value Stocks In The Healthcare Sector ↗
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
News headline image
World Markets News For Thursday ↗
Ericsson stock lost another 5.27% today in US markets. 
Via Talk Markets
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.